Asymptomatic, Enlarging Plaque: Your Dx?

News
Poll

This annular violaceous plaque, which had been present for a few months, was unresponsive to treatment for tinea corporis with topical antifungals. Which of the following statements is true?

This annular violaceous plaque, which had been present for a few months, was unresponsive to treatment for tinea corporis with topical antifungals.

Which of the following statements is true?

A. The absence of epidermal scaling argues against tinea corporis.
B. Lesion location and appearance strongly suggest granuloma annulare.
C. The patient's age also suggests granuloma annulare.
D. Dyslipidemia is positively associated with granuloma annulare.
E. Granuloma annulare is often self-limited, but topical steroids may hasten resolution.
F. All of the above are true.
Related Content
©Apogee Therapeutics

Apogee Hopes Raised by Phase 2 Data for APG777 to be a Best-In-Class for Atopic Dermatitis

Grace Halsey
July 7th 2025
Article

The investigational IL-13 inhibitor showed topline EASI-75 of 66.9% and reduced injection frequency in part A of the APEX phase 2 clinical trial. i

The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment

The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment

Sydney Jennings
July 8th 2025
Podcast

Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.

Roflumilast Cream 0.15% Receives Strong Recommendation for Atopic Dermatitis in AAD Guideline Update / image credit ©Arcutis Biotherapeutics

Roflumilast Cream 0.15% Receives Strong Recommendation for Atopic Dermatitis in AAD Guideline Update

Grace Halsey
June 26th 2025
Article

Roflumilast 0.15% is the only 1 of 4 newly evaluated branded topical therapies to receive the Academy's strong recommendation for AD management in adults.

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

Sydney Jennings
May 7th 2025
Podcast

PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.

FDA Approves Dupilumab for Treatment of Bullous Pemphigoid in Adults

FDA Approves Dupilumab for Treatment of Bullous Pemphigoid in Adults

Sydney Jennings
June 20th 2025
Article

Dupilumab is the first targeted treatment for BP to receive FDA approval, showing improved remission rates, itch reduction, and lower steroid use in pivotal trial.

/ image credit ©Billion Photos/stock.adobe.com

Teledermatology-Dermoscopy Program Could Help Reduce Inequities in Skin Cancer Screening

Grace Halsey
June 20th 2025
Article

A student-led teledermatology-dermoscopy initiative that identified skin lesions in underserved communities could be a scalable model for early skin cancer detection and care.

© 2025 MJH Life Sciences

All rights reserved.